Transcenta Holding Limited (HK:6628) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Transcenta Holding Limited has reported promising Phase II results for Osemitamab (TST001) in combination with Nivolumab and CAPOX as a first-line treatment for advanced gastric or gastroesophageal cancer, showing a median progression-free survival of 12.6 months in patients with certain biomarkers. These findings, which will be presented at ASCO 2024, could potentially improve the standard of care for HER2-negative metastatic gastric cancer patients, particularly those with lower PD-L1 expression.
For further insights into HK:6628 stock, check out TipRanks’ Stock Analysis page.